Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medifast (MED) EPS (Weighted Average and Diluted) (2016 - 2025)

Medifast's EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at -$1.65 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 2457.14% year-over-year to -$1.65; the TTM value through Dec 2025 reached -$1.71, down 1050.0%, while the annual FY2025 figure was -$1.7, 994.74% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.65 in Q4 2025 per MED's latest filing, down from -$0.21 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.96 in Q2 2021 to a low of -$1.65 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is $1.71, with a median of $2.28 recorded in 2022.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 129.33% in 2025 against a maximum downside of 2457.14% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $2.91 in 2021, then decreased by 16.49% to $2.43 in 2022, then crashed by 77.37% to $0.55 in 2023, then plummeted by 87.27% to $0.07 in 2024, then crashed by 2457.14% to -$1.65 in 2025.
  • Per Business Quant, the three most recent readings for MED's EPS (Weighted Average and Diluted) are -$1.65 (Q4 2025), -$0.21 (Q3 2025), and $0.22 (Q2 2025).